Orphan Drug Access Threatened By Medicaid Transformation, NORD Says
Executive Summary
National Organization for Rare Disorders raises concerns with proposals to limit US federal financial contributions and coverage requirements in Medicaid programs, maintaining states could limit access to orphan drugs.
You may also be interested in...
Medicaid Drug Formulary Ideas Floated, But US Manufacturers Are Skeptical
Medicaid formularies capable of excluding drugs to drive better rebates could replace the existing drug rebate program, lobbyists suggest, but US manufacturers worry that lawmakers will be leery of losing statutory-based rebates.
US Medicaid Reform: Legislators Caution CMS Nominee About Coverage Loss
Seema Verma is closely identified with Medicaid reform but both Republicans and Democrats expressed concern during her Senate confirmation hearing that reforms not translate into loss of insurance coverage.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.